THE Madras Pharmaceuticals Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: THE Madras Pharmaceuticals Pharmaceutical Export Portfolio Dataset — 6 Products, $1.6M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

THE Madras Pharmaceuticals — Pharmaceutical Exporter Profile (2026) | 6 Products, $1.6M Trade | TransData Nexus

THE Madras Pharmaceuticals

Indian Pharmaceutical Exporter · Gastrointestinal Specialist · $1.6M Total Trade · DGFT Verified

THE Madras Pharmaceuticals is an Indian pharmaceutical exporter with a total trade value of $1.6M across 6 products in 4 therapeutic categories. Based on 61 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Domperidone ($614.6K), Glucosamine ($374.2K), Secnidazole ($250.0K).

THE Madras Pharmaceuticals — Export Portfolio & Destination Treemap

THE Madras Pharmaceuticals pharmaceutical export portfolio — 6 products across 4 therapeutic categories. Source: Indian Customs (DGFT).

Who is THE Madras Pharmaceuticals? — Company Overview & Market Position

Established in 1979, The Madras Pharmaceuticals is a prominent contract research and manufacturing services (CRAMS) organization based in Chennai, India. Founded by five healthcare professionals from Madurai Medical College, the company began with a modest 2,000 sq. ft. facility and a small team. Over the years, it has expanded to encompass eight manufacturing sites, employing over 3,000 individuals, and offering a diverse range of dosage forms and therapeutic categories.

The company operates as a business-to-business (B2B) entity, focusing on out-licensing generic products developed through its in-house research and development to pharmaceutical marketing companies under supply agreements. This strategic approach ensures that The Madras Pharmaceuticals does not compete with its clients in the market.

Financially, The Madras Pharmaceuticals has demonstrated significant growth, with an annual turnover exceeding INR 500 crore (approximately $67 million USD). The company has a robust presence both domestically and internationally, with two-thirds of its business derived from the Indian market and the remaining one-third from overseas markets.

What Does THE Madras Pharmaceuticals Export? — Product Portfolio Analysis

Top Products by Export Value

1Domperidone$614.6K

Product Portfolio — Top 6 by Export Value

THE Madras Pharmaceuticals exports 6 pharmaceutical products across 4 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Domperidone	Gastrointestinal	$614.6K	25	2.1%	10
2	Glucosamine	Nutritional Supplements	$374.2K	13	2.8%	11
3	Secnidazole	Advanced Antibiotics	$250.0K	5	0.8%	9
4	Sulfasalazine	Gastrointestinal	$193.8K	8	6.0%	5
5	Acarbose	Advanced Diabetes Medications	$105.8K	6	1.6%	7
6	Chondroitin	Nutritional Supplements	$83.7K	4	1.6%	12

THE Madras Pharmaceuticals exports 6 pharmaceutical products across 4 therapeutic categories with a total export value of $1.6M. The top category is Gastrointestinal (49.8% of portfolio), followed by Nutritional Supplements (28.2%), indicating a concentrated portfolio with the top 5 products accounting for 94.8% of total export value.

THE Madras Pharmaceuticals — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

The Madras Pharmaceuticals operates eight state-of-the-art manufacturing facilities across India, each specializing in various dosage forms and therapeutic segments. These facilities are equipped with modern plants and machinery capable of producing a wide range of formulations, including tablets, hard and soft gelatin capsules, dry and liquid syrups, dry and liquid injectables, nutraceuticals, dermatological products, and hormonal products.

The company's flagship facility, established in 1979 in Chennai, has grown from an initial production capacity of 1 million tablets per month to 300 million tablets, 50 million capsules, 150,000 liters of liquids, and 0.75 tons of ointments annually.

3Key Leadership

The Madras Pharmaceuticals is led by a team of experienced professionals committed to the company's growth and ethical conduct. Mr. A.M. Sulaiman, a first-generation entrepreneur and co-founder, serves as the Managing Director. He has been instrumental in introducing the concept of contract manufacturing in India and emphasizes ethical business practices and product quality.

Dr. Nagappan, a renowned orthopedic surgeon and co-founder, plays a critical role in the group's strategy and future growth planning. Dr. Alagappan, also a co-founder and respected surgeon, contributes to the company's financial, legal, and logistical operations. Mr. Kumaran, a committed pharmaceutical professional, heads the domestic business, leveraging his extensive experience in various pharmaceutical operations. Dr. Vijay Alagappan, holding a PhD in Biomedical Engineering and an MBA in Healthcare Management, leads the international business, achieving a compound annual growth rate of 30% in exports.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does THE Madras Pharmaceuticals Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

The Madras Pharmaceuticals has made significant strides in obtaining regulatory approvals for its products in various international markets. The company has secured Good Manufacturing Practice (GMP) accreditations from multiple countries, including the European Union (EU), the United States (US), and Canada. These certifications enable the company to export its products to regulated markets, ensuring compliance with international quality standards.

In the United States, The Madras Pharmaceuticals has achieved FDA approvals for over-the-counter (OTC) and nutraceutical products, demonstrating its commitment to meeting stringent regulatory requirements. The company's EU-GMP certification further underscores its adherence to high-quality manufacturing practices, facilitating access to the European market.

2Emerging Markets

The Madras Pharmaceuticals has strategically expanded its presence in emerging markets across Africa, Latin America, and Southeast Asia. The company has obtained GMP accreditations from countries such as Ethiopia, Kenya, Uganda, Tanzania, Nigeria, Sri Lanka, Myanmar, Nepal, the Philippines, Cambodia, Zimbabwe, and various nations in the South American region.

These certifications enable The Madras Pharmaceuticals to supply its products to a diverse range of markets, addressing the growing demand for quality pharmaceuticals in these regions. The company's proactive approach in obtaining these approvals reflects its commitment to global expansion and meeting the healthcare needs of various populations.

THE Madras Pharmaceuticals — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

The Madras Pharmaceuticals has achieved significant milestones in obtaining approvals from the U.S. Food and Drug Administration (FDA). The company's manufacturing facilities are registered with the FDA, and it has received approvals for over-the-counter (OTC) and nutraceutical products, demonstrating compliance with stringent U.S. regulatory standards.

The company's commitment to quality is further evidenced by its adherence to FDA guidelines, ensuring that its products meet the safety and efficacy standards required for the U.S. market. This regulatory compliance enhances The Madras Pharmaceuticals' credibility and facilitates its entry into the competitive U.S. pharmaceutical market.

2WHO & EU GMP

The Madras Pharmaceuticals has obtained Good Manufacturing Practice (GMP) certifications from the World Health Organization (WHO) and the European Union (EU), underscoring its commitment to maintaining high-quality manufacturing standards. These certifications enable the company to export its products to various international markets, including the EU and countries recognized by the WHO.

The EU-GMP certification, in particular, facilitates access to the European market, allowing The Madras Pharmaceuticals to supply its products to a region with stringent quality requirements. These certifications reflect the company's dedication to meeting international standards and expanding its global presence.

THE Madras Pharmaceuticals — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

The Madras Pharmaceuticals operates in a competitive landscape, facing numerous contract research and manufacturing services (CRAMS) organizations both domestically and internationally. Key competitors include companies such as Jubilant Life Sciences, Aurobindo Pharma, and Dr. Reddy's Laboratories, which also offer a range of manufacturing services and have established global presences.

In terms of market share, The Madras Pharmaceuticals holds a significant position in the Indian market, with a turnover exceeding INR 500 crore (approximately $67 million USD). While specific market share data for international markets is not publicly available, the company's extensive list of GMP accreditations and regulatory approvals indicates a strong competitive position in various regions.

The company's focus on quality, ethical business practices, and customer satisfaction differentiates it from competitors. By maintaining high standards and ensuring compliance with international regulations, The Madras Pharmaceuticals enhances its reputation and appeal to potential clients seeking reliable manufacturing partners.

2Key Differentiators

The Madras Pharmaceuticals distinguishes itself through several key strengths:

Comprehensive Manufacturing Capabilities:

Frequently Asked Questions — THE Madras Pharmaceuticals

How many pharmaceutical products does THE Madras Pharmaceuticals export from India?

THE Madras Pharmaceuticals exports 6 pharmaceutical products across 4 therapeutic categories. The top exports are Domperidone ($614.6K), Glucosamine ($374.2K), Secnidazole ($250.0K), Sulfasalazine ($193.8K), Acarbose ($105.8K). Total export value is $1.6M.

What is THE Madras Pharmaceuticals's total pharmaceutical export value?

THE Madras Pharmaceuticals's total pharmaceutical export value is $1.6M, based on 61 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does THE Madras Pharmaceuticals cover?

THE Madras Pharmaceuticals exports across 4 therapeutic categories. The largest are Gastrointestinal (49.8%, 2 products), Nutritional Supplements (28.2%, 2 products), Advanced Antibiotics (15.4%, 1 products).

Get Full THE Madras Pharmaceuticals Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.